EP1013-F1013-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEEP1013Cat. No.: HY-10397CAS No.: 223568-55-6Synonyms: F1013分式: CHFNO分量: 382.38作靶點: Caspase作通路: Apoptosis儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 60 mg/mL (156.91 mM)* means soluble,

2、but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.6152 mL 13.0760 mL 26.1520 mL5 mM 0.5230 mL 2.6152 mL 5.2304 mL10 mM 0.2615 mL 1.3076 mL 2.6152 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 EP1013種譜的 caspase 選擇性抑制劑，可于 1 型糖尿病研究。IC50 & Target Caspase體

3、內(nèi)研究EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEEP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversalrate for this group isnot significantly different from

4、the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. EP1013therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function 1.REFERENCES1. Emamaullee JA, et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islettransplantation in mice. Diabetes. 2008 Jun;57(6):1556-66.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;F